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REGULAR ARTICLE
C/EBPa overrides epigenetic reprogramming by oncogenic transcription
factors in acute myeloid leukemia
Justin Loke,* Paulynn Suyin Chin,* Peter Keane, Anna Pickin, Salam A. Assi, Anetta Ptasinska, Maria Rosaria Imperato, Peter N. Cockerill, and
Constanze Bonifer
Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
Key Points
•C/EBPa directly re-
presses the leukemia
maintenance program;
however, the pattern of
repressed genes is
specific for each type of
AML.
•Overexpression of
C/EBPa does not
globally displace these
proteins from their
binding sites, but over-
rides their repressive
activity.
Acute myeloid leukemia (AML) is a heterogeneous disease caused by recurrent mutations in
the transcription regulatory machinery, resulting in abnormal growth and a block in
differentiation.One typeof recurrentmutations affectsRUNX1, which is subject tomutations
and translocations, the latter giving rise to fusion proteins with aberrant transcriptional
activities. We recently compared themechanism bywhich the products of the t(8;21) and the
t(3;21) translocation RUNX1-ETO and RUNX1-EVI1 reprogram the epigenome. We demon-
strated that a main component of the block in differentiation in both types of AML is direct
repression of the gene encoding the myeloid regulator C/EBPa by both fusion proteins. Here,
we examined at the global level whether C/EBPa is able to reverse aberrant chromatin
programming in t(8;21) and t(3;21) AML. C/EBPa overexpression does not change
oncoprotein expression or globally displace these proteins from their binding sites. Instead,
it upregulates a core set of common target genes important for myeloid differentiation and
represses genes regulating leukemia maintenance. This study, therefore, identiﬁes common
CEBPA-regulated pathways as targets for therapeutic intervention.
Introduction
The RUNX1 transcription factor is frequently mutated in acute myeloid leukemia (AML).1 Translocations
of its gene result in the production of core-binding factor (CBF) fusion proteins. One fusion partner is
RUNX1T1 (ETO), which is generated by the t(8;21) translocation2 and is found in ;12% of younger
patients with AML.3 Another fusion partner is MECOM (EVI1) in cells with the t(3;21) translocation.4,5
The fusion partner in each translocation has different roles in leukemogenesis. Evi1 is an essential
regulator of self-renewal in hematopoietic stem cells.6 Its overexpression is a common finding in AML
patients and is an independent poor prognostic factor on multivariate analysis.7 In contrast, knockout of
Mtg8 (ETO) in mice does not result in hematopoietic defects.8
We recently demonstrated that despite carrying the same DNA-binding domain (Figure 1), the expression
of each fusion protein drives the formation of a unique gene regulatory network,9 with both oncoproteins
binding to different genomic sites. RUNX1-EVI1 drives a more stem cell–like transcriptional network than
RUNX1-ETO, explaining the difference in prognoses of patients with each form of AML.3,10 Both forms of
AML are dependent on the continued presence of their fusion proteins because their depletion by small
interfering RNA (siRNA) results in the initiation of a myeloid differentiation process that is dependent on
transcription factor C/EBPa.9,11-14 Blocking C/EBPa activity abrogates the differentiation response
triggered after depletion of either fusion protein.9,15 After knockdown of either RUNX1 fusion protein,
C/EBPa binds to thousands of new genomic sites, increasing chromatin accessibility and recruiting other
transcription factor partners, such as RUNX1.9,15 This requirement for C/EBPa to activate a myeloid
differentiation response reflects the results of previous knockout models showing that this transcription
Submitted 25 September 2017; accepted 2 January 2018. DOI 10.1182/
bloodadvances.2017012781.
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factor is required for hematopoietic cells to transit to granulocyte-
monocyte precursors (GMPs)16 and that in its absence, neutrophil
development fails.17
Others have previously shown that C/EBPa overexpression is
sufficient to trans-differentiate lymphocytes into myeloid cells18-20
and is able to initiate myeloid differentiation in RUNX1-ETO–
expressing cells.21 Similarly, simultaneous expression of C/EBPa
rescued the RUNX1-EVI1–mediated block of a differentiation
response in a model cell line.22 Therefore, overexpression of
C/EBPa could be a versatile treatment approach in the manage-
ment of AML. However, the global mechanism by which C/EBPa
drives this differentiation response is not known. It is unclear which
genes are targeted by C/EBPa and how binding impacts on fusion
protein binding. Most importantly, it is not known whether C/EBPa
targets a similar set of genes driving myeloid differentiation in both
types of AML. Understanding the mechanism by which C/EBPa
acts is critical in determining which forms of AML may benefit from
this treatment. In this study, we used t(3;21) and t(8;21) cell lines
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Figure 1. Response to knockdown of RUNX1-EVI-1 and RUNX1-ETO converges on a C/EBPa-driven differentiation program. (A) Structure of RUNX1-EVI1 and
RUNX1-ETO. NHR, nervy homology region; RD, proline-rich repressive domain; RHD, Runt homology domain; SET, Su(var)3-9 and enhancer of zeste and trithorax; ZF, zinc
finger domain. (B) Hierarchical clustering of GO terms for upregulated or downregulated genes (1.5-fold difference) after either RUNX1-EVI1 or RUNX1-ETO knockdown
compared with control siRNA. Expression after treatment was measured after 10 days in SKH-1 cells or 4 days in Kasumi-1 cells. The blue box identifies GO terms commonly
upregulated after knockdown of both RUNX1-ETO and RUNX1-EVI1. (C) Selected examples of upregulated or downregulated genes.
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as a model to address these questions. We expressed an
inducible version of C/EBPa20 and subsequently character-
ized how overexpression reprogrammed gene expression
and transcription factor occupancy. We show that C/EBPa
overexpression does not cause the removal of the fusion proteins
from their binding sites, but activates a core of genes common to
both types of AML and overrides the block in differentiation,
highlighting similar targets for therapeutic intervention.
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Figure 2. C/EBPa overexpression drives cells into differentiation and apoptosis. (A) C/EBPa-ER fusion translocates to the nucleus when bound to 17b-estradiol
(E2). (B-C) Flow cytometry of mock or C/EBPa-ER–transduced Kasumi-1 or SKH-1 cells treated with either ethanol (ETOH) or 10 nM-1mM E2 for 2-4 days. (B) Mean
fluorescence intensity (MFI) (median) of CD11b and annexin V conjugated to allophycocyanin (APC) staining relative to ethanol treated, mock transduced Kasumi-1 or SKH-1.
The graph shows the mean of 3 independent experiments with standard error of the mean (SEM). *P , .05, paired Student t test. (C) Representative overlay of flow cytometry
histograms of cells stained with CD11b-APC. (D-E) Annexin-V APC in mock-treated or C/EBPa-ER–transduced Kasumi-1 or SKH-1 cells treated with either vehicle (ethanol)
or 10 nM E2 followed by flow cytometry (2 days in SKH-1, 4 days in Kasumi-1). (D) Percentage of Annexin-V–positive cells. Mean and SEM of 3 independent experiments.
*P , .05 by paired Student t test. (E) Representative plots are shown. C/EBPa-ER–transduced cells express GFP. (F) Kasumi-1 or SKH-1 cells were either mock treated or
transduced with C/EBPa-ER virus. Induced and uninduced transduced cells were treated (2 days in SKH-1, 4 days in Kasumi-1) before plating on methylcellulose culture.
Colonies of .20 cells were counted between 7 and 11 days after plating. The graph shows the mean of at least 4 experiments, with error bars representing SEM. *P , .05 by
paired Student t test.
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Materials and methods
Detailed methods can be found in supplemental Materials and
methods.
Cell culture
Cells were maintained in a humidified incubator at 37°C with 5%
CO2. t(3;21) SKH-1 cells were cultured in RPMI 1640 medium with
10% fetal calf serum (FCS). t(8;21) Kasumi-1 cells were cultured in
RPMI 1640 with 15% FCS. HEK293T cells were cultured in
Dulbecco’s modified Eagle medium (DMEM) with 10% FCS.
Western blotting, RNA extraction, complementary
DNA synthesis, and reverse transcription polymerase
chain reaction
RNA was isolated using Trizol (Life Technologies) and treated with
Ambion Turbo DNaseI (Thermos Fisher Scientific). The RNA
solution was then purified using a Nucleospin RNA Clean-up
column (Macherey-Nagel). The quality of RNA was assessed using
a Total RNA PICO Bioanalyzer chip (Agilent). Western blotting,
complementary DNA synthesis, and quantitative reverse transcrip-
tion polymerase chain reaction (RT-qPCR) was performed as
described previously.11 Antibodies and primers are listed in
supplemental Materials.
RNA sequencing
RNA sequencing (RNA-seq) libraries were prepared with a Total
RNA Ribo-zero library preparation kit (with ribosomal RNA de-
pletion; Illumina) according to the manufacturer’s instructions with
some modifications (supplemental Materials).
Flow cytometry and apoptosis assay
Flow cytometry and apoptosis assays were performed as previously
described.9 The antibodies used for flow cytometry are listed in the
supplemental Table 1.5.
Transfection of HEK293T cells for C/EBPa-ER
virus production
C/EBPa-estrogen receptor (ER) plasmid was a gift of Thomas
Graf (Barcelona, Spain). The following plasmids were mixed:
backbone vector containing the transgene (36 mg), Tat (1.2 mg),
Gag/Pol (30 mg), and Env (9 mg; gift from James Mulloy,
Cincinnati, OH). For each 10-cm2 dish, 1.5 mL of OptiMEM
serum-free media was mixed with 75 mL of TransIT-293 (Mirius)
and incubated at room temperature for 15 minutes. The TransIT-
293–DNA mixture was added dropwise to the HEK293T cell
plate. Viral supernatant was collected after 48 hours and
subsequently every 12 hours for 36 hours. Viral supernatant was
concentrated using a Centricon Plus-70 100-kDa filter (Millipore)
according to manufacturer’s instructions.
Retroviral transduction with RetroNectin
Non–tissue culture plates were incubated with 2 mg/mL Retro-
Nectin (Takara) solution in phosphate-buffered saline. Concen-
trated virus was coated onto the wells by centrifugation before
Kasumi-1 or SKH1 cells were added with polybrene at 8 mg/mL.
The plate was left overnight at 37°C, 5% CO2 in a humidified
incubator. Transduced SKH1 cells were isolated by fluorescence-
activated cell sorting using GFP labeling.
Cross-linking, ChIP, and library preparation for
high-throughput sequencing
Cross-linking, chromatin immunoprecipitation (ChIP), and library
preparation for high-throughput sequencing was performed as
previously described.9,15,23 Full details with primer and antibody
details can be found in supplemental Materials.
Data analysis
The full details of the bioinformatics analysis can be found in the
supplemental Materials and methods (section 1.3).
Results
Knockdown of RUNX1-ETO and RUNX1-EVI1 changes
expression of a core set of genes, including CEBPA
The t(3;21) and t(8;21) translocations result in the retention of
the RUNT homology DNA-binding domain of RUNX1 (Figure 1A),
but both fusion proteins differentially reprogram the epigenetic
landscape through different binding partners and genomic
targets.9 Here, we sought to identify biological processes
regulated by both proteins, because they may represent common
therapeutic targets for different types of CBF AML. We therefore
compared the gene expression changes on siRNA-mediated
knockdown of either RUNX1-ETO11 or RUNX1-EVI19 by RNA-seq
and performed a hierarchical clustering of the Gene Ontology
(GO) terms to identify processes disrupted by both oncogenes
(Figure 1B). In these experiments, we used the t(3;21) cell line
SKH1 expressing RUNX1-EVI14 and the t(8;21) cell line Kasumi-1
expressing RUNX1-ETO.24 Reflective of the differing cellular
origins of both cell types, few GO terms were commonly up- or
downregulated in each type of AML. However, genes responding
to fusion protein depletion highlighted commonly deregulated
pathways in both AML types. Common downregulated genes
encoded stem cell regulators, such as ERG and GATA2, whereas
upregulated genes included CEBPA and the myeloid growth
factor receptor genes CSF3R and CSF1R (Figure 1C; supple-
mental Table 2).
A total of 136 genes were differentially expressed in t(3;21) SKH-1
and t(8;21) Kasumi-1 cells after knockdown of their respective
CBF fusion protein (supplemental Table 2). We next identified
whether overexpression of such upregulated genes could re-
produce the system-wide effects of fusion protein depletion. Here,
we concentrated on CEBPA, because previous work showed that
this gene was directly repressed by each fusion protein in both
types of AML, and the initiation of differentiation after their
depletion was dependent on C/EBPa, which occupied a large
number of novel binding sites after knockdown.9,15 Reanalysis of
data from DNAse-sequencing experiments, after knockdown of
either fusion protein identifying the changes in chromatin
accessibility,9,11,15 in both cell types showed that CEBP motifs
were uniquely found in newly formed DNaseI hypersensitive sites
(supplemental Figure 1A-B). Fusion protein genes and CEBPA
act in the same pathway, as shown by the reanalysis of publicly
available data from cohorts of independently treated patients with
AML showing that: (1) CEBPA is commonly downregulated in
CBF AML as compared with AML with normal karyotype
(supplemental Figure 1C); and (2) mutations in CEBPA and
CBF translocations in AML were mutually exclusive (supplemental
Figure 1D).
274 LOKE et al 13 FEBRUARY 2018 x VOLUME 2, NUMBER 3
Lo
g2
 F
P
K
M
6
2
t(8;21) Kasumi-1
Mock C/EBP-ER
ETO
H
17
E2ETO
H
17
E2
Mock C/EBP-ER
t(3;21) SKH1
ETO
H
17
E2ETO
H
17
E2
A
Kasumi-1
SKH-1
C/EBP-ER
p = 1.8 x 10-147
Up-regulated genes
RUNX1-ETO
knock-down
441 312 561
p = 7.3 x 10-84
C/EBP-ER RUNX1-EVI1
knock-down
848 193 261
p = 9.9 x 10-85
C/EBP-ER RUNX1-ETO
knock-down
Down-regulated genes
552 221 477
p = 2.1 x 10-62
C/EBP-ER RUNX1-EVI1
knock-down
737 192 449
C
Kasumi-1
Up regulated by C/EBP-ER 
En
ric
hm
en
t s
co
re
 (E
S)
Ra
nk
ed
 lis
t m
et
ric
(L
og
2 
of
 ra
tio
 c
las
se
s)
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
5.0
2.5
0.0
-2.5
-5.0
0 2500 5000 7500 10000
Rank in ordered dataset
Enrichment profile Hits Ranking metric score
En
ric
hm
en
t s
co
re
 (E
S)
Ra
nk
ed
 lis
t m
et
ric
(L
og
2 
of
 ra
tio
 c
las
se
s)
Down regulated by C/EBP-ER 
Rank in ordered dataset
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
5.0
2.5
0.0
-2.5
-5.0
0 2500 5000 7500 10000
SKH-1
Up regulated by C/EBP-ER 
En
ric
hm
en
t s
co
re
 (E
S)
Ra
nk
ed
 lis
t m
et
ric
(L
og
2 
of
 ra
tio
 c
las
se
s)
Rank in ordered dataset
0.5
0.4
0.3
0.2
0.1
-0.1
0.0
5.0
2.5
0.0
-2.5
0 2000 4000 6000 8000
Down regulated by C/EBP-ER 
En
ric
hm
en
t s
co
re
 (E
S)
Ra
nk
ed
 lis
t m
et
ric
(L
og
2 
of
 ra
tio
 c
las
se
s)
Rank in ordered dataset
-0.1
-0.2
-0.3
-0.4
-0.5
-0.6
0.0
5.0
2.5
0.0
-2.5
0 2000 4000 6000 8000
B
NES = 2.36
p,q < 0.0001
NES = -2.567
p,q < 0.0001
NES = 2.36
p,q < 0.0001
NES = -2.57
p,q < 0.0001
Figure 3. C/EBPa induction and CBF fusion protein knockdown induce similar changes in the transcriptional program. (A) Hierarchical clustering of RNA-seq
data by log2 fold FPKM (fragments per kilobase of transcripts per million mapped reads) values of genes differentially expressed (twofold change) after C/EBPa
induction by E2 or vehicle as indicated (4 days for Kasumi-1 and 2 days for SKH-1). (B) Comparison of up- and downregulated genes after C/EBPa-ER induction in
Kasumi-1 and SKH1 cells with genes changing expression after RUNX1-ETO and RUNX1-EVI1 knockdown (KD) or control siRNA treatment (MM). (C) Number of
genes changing expression at least 1.5-fold after C/EBPa induction in Kasumi-1 and SKH1 cells as compared with RUNX-EVI1 or RUNX1-ETO knockdown. The
P values in panel C were calculated with Fisher’s exact test using the total set of genes expressed in each condition as the background.
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Overexpression of C/EBPa leads to dramatic changes
in gene expression and initiation of differentiation
We next used an inducible version of CEBPA (C/EBPa-ER) to
examine whether its upregulation was sufficient to replicate
the dramatic changes in gene expression patterns and binding
profiles observed after knockdown of RUNX1-EVI1 or RUNX1-
ETO. The C/EBPa-ER retrovirus encodes a C/EBPa protein
fused to an ER ligand-binding domain (Figure 2A), which
translocates into the nucleus on binding to 17b-estradiol
(E2).25 We stably expressed this construct in both the SKH1
and Kasumi-1 cell lines (supplemental Figure 2A) and treated
the cells either with vehicle (ethanol [EtOH]) or E2. Activation
of C/EBPa-ER upregulated cell surface expression of the
myeloid marker CD11b in both Kasumi-1 and SKH1 cells
(Figure 2B). We and others previously have shown that
knockdown of RUNX1-ETO14 and RUNX1-EVI19 downregu-
lates the stem and progenitor cell marker CD34. Induction of
C/EBPa-ER activity led to significant decreases in CD34 in
SKH1 cells (supplemental Figure 2B-C). In Kasumi-1, the
messenger RNA expression of CD34 decreased (supplemen-
tal Table 3), at this time point the protein was still seen on the
surface. However, CD117 surface expression characterizing
primitive hematopoietic cells capable of self-renewal26 was
downregulated (supplemental Figure 2E). We and others have
previously shown that after knockdown of RUNX1-ETO or
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Figure 5. C/EBPa induction drives similar pathways in both cell lines. (A-B) C/EBPa induction predominantly upregulates target genes in both Kasumi-1 and SKH1
cells. Table showing numbers of either (A) upregulated or (B) downregulated genes, which are bound by either RUNX1-ETO or RUNX1-EVI1, with and without C/EBPa.
Bar graph showing this data as a percentage of differentially expressed genes. (C-D) Enriched KEGG pathways identified from genes differentially expressed after C/EBPa
induction and bound by either C/EBPa, RUNX1-ETO, or RUNX1-EVI1. KEGG pathway from (C) upregulated genes and (D) downregulated genes.
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RUNX1-EVI1, cells enter apoptosis.9,14 The same was seen
after C/EBPa-ER induction in these cell lines, which inhibited
growth as well (Figure 2D-E; supplemental Figure 2F). Finally,
colony-forming ability was reduced after C/EBPa-ER induction
in terms of both total numbers (Figure 2F) and size (supple-
mental Figure 2G).
Given the similarities in cellular response between the fusion
protein knockdown and the induction of C/EBPa-ER activity in
both cell lines, we examined the genomic response to C/EBPa-
ER overexpression at the global level by performing RNA-seq in
either mock-treated Kasumi-1/SKH1 cells or C/EBPa-ER–
transduced Kasumi-1/SKH1 cells after vehicle (EtOH) or E2
induction in all cell types (Figure 3A; supplemental Figure 3A).
These experiments showed that all control cells displayed a
similar gene expression pattern which changed dramatically
after C/EBPa-ER induction (Figure 3A). We compared this data
with changes in gene expression patterns after RUNX1-ETO
and RUNX1-EVI1 depletion9,15 using gene set enrichment
analysis (GSEA). Figure 3B shows that the pattern of up- and
downregulated genes after C/EBPa-ER induction and fusion
protein depletion were highly similar. In addition, we found a
distinct overlap between genes changing expression after
C/EBPa-ER induction and fusion protein knockdown in both
cell types (Figure 3C; supplemental Table 3). The overlap in
Kyoto Encyclopedia of Genes and Genomes (KEGG) and GO
terms was small and was mostly restricted to upregulated genes
(supplemental Figure 3B-E).
C/EBPa overexpression and fusion protein depletion
reshape the C/EBPa-binding landscape in both types
of AML
To identify the shared targets of C/EBPa in both cell types, we
determined its binding sites using ChIP assays before and after E2
induction using an antibody recognizing both the endogenous and
induced version of C/EBPa. In both cell lines, induction resulted in
C/EBPa losing as well as gaining new binding sites, indicating that
the cells entered an altered differentiation state (Figure 4A-D).
C/EBPa bound predominantly to sites distal to the promoter, and
this general pattern was not affected by induction of C/EBPa-ER
(supplemental Figure 4A).
For both cell types, we aligned the ChIP sequences with C/EBP-,
ETS-, AP-1–, GATA-, and RUNX-binding motifs, because the
motifs bound by these factor families determine the transcriptional
networks regulating t(8;21) and t(3;21) cells9 (Figure 4A,C,
middle). In both cell types, C/EBP motifs were evenly distributed in
all C/EBPa-binding sites regardless of cell type or experimental
condition. However, we also identified cell line–specific motif
patterns in C/EBPa-binding sites: a predominance of RUNX and
ETS motifs in Kasumi-1, and in SKH1, novel C/EBPa-binding was
characterized by an absence of underlying GATA motifs. This is in
keeping with our previous finding of the importance of GATA2 in
maintaining t(3;21) but the t(8;21) leukemia.9 The comparison
of total C/EBPa-binding sites after induction in t(8;21) and
t(3;21) cells identified a considerable overlap but also multiple
specific sites, indicating that the 2 cell types entered a common
differentiation program but were not identical (supplemental
Figure 4B-C).
We also examined the relationship between induced C/EBPa
binding and C/EBPa binding after fusion protein knockdown. As
shown in Figure 4A,C, novel C/EBPa-bound sites after knockdown
of RUNX1-ETO or RUNX1-EVI1 and induced C/EBPa-bound sites
overlap considerably. An example (CXCR4) is shown in supple-
mental Figure 4D. We defined C/EBPa target genes as those
harboring a C/EBPa ChIP sequencing (ChIP-seq) peak within
100 kb of their promoter. C/EBPa induction primarily upregulated
its target genes in both Kasumi-1 and SKH1 cells (Figure 5A-B),
which is in keeping with previously conducted reporter gene
assays.27,28 In contrast, C/EBPa induction of RUNX1-ETO– or
RUNX1-EVI1–only targets led to both up- and downregulation of
gene expression. However, genes bound by both C/EBPa and the
CBF fusion protein were primarily upregulated, suggesting that
C/EBPa-driven gene activation dominated the interaction between
the transcription factors. This pattern of gene regulation was
retained when we analyzed the genes that were differentially
expressed after both C/EBPa overexpression and CBF fusion
protein knockdown (supplemental Figure 5A-B; supplemental
Table 4). The genes targeted by both C/EBPa and CBF fusion
proteins represent a number of important pathways required for the
function of terminally differentiated myeloid cells (Figures 5C-D and
6E; supplemental Table 5). Together with the similarity in
phenotypic changes seen after both C/EBPa overexpression and
CBF fusion protein knockdown, these results suggest that common
target genes of fusion proteins and C/EBPa in both models are the
primary driver of these changes.
Many of the pathways upregulated after the induction of C/EBPa
were common to both cell lines and after both C/EBPa
overexpression and CBF fusion protein knockdown (Figure 5C-D).
The overlap between the 2 cell lines in terms of key down-
regulated pathways was smaller, suggesting that each type of
AML uses different means to maintain its leukemic state.
For example, MEIS1 was downregulated in SKH1 after either
RUNX1-EVI1 knockdown or C/EBPa overexpression but not in
Kasumi-1. An exception to this is the gene encoding the
transcription factor MEF2C (supplemental Figure 5C). An
Figure 6. C/EBPa overrides rather than displaces RUNX1-ETO or RUNX1-EVI1. (A-D) De novo RUNX1-ETO or RUNX1-EVI1 bound sites after E2 treatment are also
bound by C/EBPa. Overlap of sites bound by either RUNX1-ETO (A) or RUNX1-EVI1 (C) after either ethanol or E2 treatment of cells. (B,D) ChIP-seq profiles of either
RUNX1-ETO (B) or RUNX1-EVI1 (D) ranked from top to bottom in order of decreasing relative DNA sequence tag count for peaks identified after E2 and vehicle treatment.
Aligned to the same coordinates are C/EBPa ChiP-seq tag counts in cells treated with either ethanol or E2. (E-F) GSEA of genes close to sites with altered RUNX1-ETO and
RUNX1-EVI1 binding after C/EBPa induction in Kasumi1 and SKH1 cells. Comparison of gene expression profiles of these genes to HSC and monocyte expression patterns.
(E) Increased binding of RUNX1-ETO and RUNX1-EVI1 after C/EBPa upregulation occurs at monocyte-associated genes and is associated with increased expression. (F)
Decreased binding of RUNX1-ETO and RUNX1-EVI1 after C/EBPa upregulation occurs at HSC-associated genes, which are downregulated.
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example of a commonly upregulated gene is CSF3R, which was
bound by both transcription factors in both cell lines (supple-
mental Figure 5D).
C/EBPa does not globally displace fusion proteins
The expression of both oncogenes was unaffected by the increase
in C/EBPa activity (supplemental Figure 6A). Given the large
overlap between C/EBPa and fusion protein binding, C/EBPa
could drive cells into differentiation by either displacing fusion
proteins from their binding site or by overriding their repressive
action. To this end, we analyzed fusion protein binding in induced
and uninduced C/EBPa-ER–transduced cells. In spite of the
overlap between binding sites, the binding sequences of either
RUNX1-ETO or RUNX1-EVI1 closely correlated irrespective of the
presence of C/EBPa, whereas C/EBPa-bound sequences clus-
tered differently in Kasumi-1 cells and to a lesser extent in SKH1
cells (supplemental Figure 6B). Under all 4 experimental conditions,
both CBF fusion proteins mainly bound distal to the promoters
(supplemental Figure 6C). C/EBPa induction did not lead to
fusion protein displacement (Figure 6A-D). The reduction of
RUNX1-EVI1 and RUNX1-ETO at specific sites did not show
increased C/EBPa binding (Figure 6B). Instead, RUNX1-ETO
and RUNX1-EVI1 moved to novel binding sites (Figure 6B,D;
supplemental Figure 6D-E). We hypothesized that this shift was
caused by the onset of myeloid differentiation and the activa-
tion of monocyte-specific cis-regulatory elements. To test this
hypothesis, we compared the expression of these genes
associated with such new sites with publicly available monocyte
and hematopoietic stem cell (HSC) gene expression data using
GSEA.29 Our data indeed show that increased RUNX1-ETO
and RUNX1-EVI1 binding occurs close to monocyte-specific
genes, which become upregulated. Conversely, after C/EBPa
induction, RUNX1-ETO and RUNX1-EVI1 binding decreases at
genes expressed in self-renewing HSCs, which become down-
regulated (Figure 6E-F).
Finally, we asked whether the same genes and pathways
regulated by CEBPA overexpression in our cell lines were
similar to those differentially regulated in patients with t(8;21)
AML. We show that the same genes and pathways upregulated
by CEBPA overexpression in Kasumi1 cells are repressed in 2
independent cohorts of patients with t(8;21) AML as compared
with normal karyotype AML (Figure 7; supplemental Table 6).
However, the pathways repressed by C/EBPa induction were
not correlated with those highly expressed in patient samples
(supplemental Figure 7). The likely reason for the latter finding
is that many of these genes are RUNX1-ETO targets, and
RUNX1-ETO is still present in such cells as compared with
karyotypically normal AML and drives the expression of a
different set of genes.
In summary, we show that C/EBPa overexpression is sufficient
to phenocopy to a large extent the global genomic response
after knockdown of either CBF fusion protein. Although
both types of AML maintain their leukemic phenotype by
using different self-renewal pathways, C/EBPa is capable of
downregulating both while simultaneously upregulating re-
lated pathways for differentiation and apoptosis. It performs
these functions not by displacing or downregulating fusion
protein expression, but by overriding their repressive activity
(Figure 7).
Discussion
The genomic response to knockdown of CBF fusion
proteins in t(3;21) and t(8;21) AML converges on a
core transcriptional output governed by C/EBPa
Despite both t(8;21) and t(3;21) leukemia originating from translo-
cations involving the RUNX1 gene, both types of AML have a
different clinical outlook.3,10 This clinical heterogeneity is reflected
in the unique gene regulatory network that drives each type of AML,
resulting in differing transcription factor dependencies.9 Although
t(8;21) but not t(3;21) AML survival is dependent on the expression
of the unaffected RUNX1 allele,30 t(3;21) but not t(8;21) AML is
dependent on the expression of GATA2.9 However, the survival and
block in differentiation for both types of AML is dependent on the
continuous presence of their respective fusion proteins. In both
cases, CEBPA is a direct target of fusion protein repression and is
required for the differentiation response after their depletion.9,15
Here, we show that C/EBPa overexpression is sufficient to
reprogram the epigenetic landscape of both types of AML, despite
the continued presence of either CBF fusion protein. The initiation
of myeloid differentiation and enhanced apoptosis seen after
C/EBPa induction mimicked the phenotype seen after knockdown
of either RUNX1-ETO or RUNX1-EVI1 (Figure 2). Moreover, in both
types of AML, for upregulated genes, there was a large overlap in
the target gene response between C/EBPa induction and fusion
protein knockdown. Commonly upregulated genes included other
members of the CEBP transcription factor family, includingCEBPD
and CEBPE. CEBPE is required for the terminal differentiation
of neutrophils,31 whereas CEBPD is required for the full function
of macrophages.32 The importance of CEBPA repression in
maintaining the leukemogenic phenotype of t(8;21) AML is validated
by the finding that C/EBPa induction in our experimental models
activated pathways that were repressed in primary t(8;21) AML
samples (Figure 7; supplemental Figure 7).
C/EBPa induction downregulates the leukemia
maintenance program
There was little or no overlap in the gene expression pattern for
downregulated genes, confirming that both types of AML maintain
the leukemic phenotype via different gene regulatory networks.
However, a significant proportion of C/EBPa target genes were
repressed by the binding of C/EBPa after induction (Figure 5).
C/EBPa therefore plays a vital role in deactivating the leukemia
maintenance program. This repressive capacity of C/EBPa is an
important homeostatic mechanism by which HSCs maintain
quiescence. CEBPA knockout activates Mycn in HSCs and
increases their proliferation; C/EBPa directly represses mycn in
murine HSC.33 In addition, C/EBPa is capable of controlling cell
cycle progression through interaction with E2F1.34 In vitro, C/EBPa
directly represses E2F complex transactivation of target constructs.35
One gene included in the small group of C/EBPa target genes that
were downregulated in both cell lines after either C/EBPa induction
or fusion protein knockdown is the gene encoding the transcription
factor MEF2C (supplemental Figure 5C). Consistent with this
notion, expression of MEF2C and CEPBA is negatively correlated
in patients with CML.36 Overexpression of MEF2C is a poor
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Figure 7. C/EBPa overexpression in Kasumi-1 cells upregulates pathways repressed in primary t(8;21) samples. (A-B) GSEA based on RNA-seq of Kasumi1 after
overexpression of C/EBPa. Enrichment of genes that are upregulated in this process in comparison with genes that are repressed in primary t(8;21) as compared with normal
karyotype AML samples in both the (A) Verhaak et al cohort52 and (B) The Cancer Genome Atlas (TCGA) cohort53 of patients with AML. (C-D) Model of the C/EBPa-
mediated override of t(8;21) and t(3;21) AML transcriptional networks. (C) t(3;21) and t(8;21) AML are epigenetically different AMLs, but (D) overexpression of C/EBPa results
in upregulation (blue lines) of myeloid differentiation genes, which also become bound by the fusion proteins, and repression (red lines) of select genes required for stem cell
function.
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prognostic factor in pediatric AML,37 and it is highly expressed
in immature pediatric T-cell acute lymphoblastic leukemia.38
Overexpression of MEF2C in GMPs results in increased self-
renewal, and MEF2C expression is required for MLL-AF9 AML
transformation of committed GMPs.39
C/EBPa overrides the activity of CBF fusion proteins
without their displacement
Our study demonstrates that in the majority of genes, induced
C/EBPa binding to fusion protein targets increases their expression
(Figure 5), and this is an important finding in the context of the ability
of the CBF fusion proteins to recruit transcriptional repressors. A
corepressor complex interacts with RUNX1-ETO through the NHR
domains40,41 and the ability of RUNX1-ETO to repress transcription
has been shown to be dependent on its ability to associate with
N-CoR,42 which recruits histone deacetylases.43 RUNX1-EVI1
binds CtBP,22 which is also a transcriptional corepressor.44 Our
data point to a model whereby the balance between C/EBPa and
fusion protein activity directly regulates target gene expression, with
low levels of transcriptionally active C/EBPa unable to counteract
repressive fusion protein activity (Figure 7). It has previously been
shown that the C/EBPa N-terminal transactivation domain is
responsible for the transcriptional activation capacity of C/EBPa45
through its interaction with the basal transcriptional machinery, such
as TBP and TFIIB.46 This ability to assemble the core transcriptional
complex may be the basis by which C/EBPa dominates the
transcriptional output of target genes, even when bound simulta-
neously by the CBF fusion proteins. In addition, C/EBPa may exist in
a concentration-dependent dynamic equilibrium with fusion proteins.
Fusion protein binding after C/EBPa induction was not static
(Figure 6), which is reminiscent of our previous data showing that
after RUNX1-EVI1 depletion, C/EBPa initiates the formation of new
DNaseI hypersensitive sites and is required to recruit normal
RUNX1 to these sites,9 possibly via interaction with SWI/SNF
nucleosome remodeling complexes.47 The ability to corecruit other
transcription factors may be the mechanism behind the observation
that C/EBPa is required for the development of Hoxa9/Meis1 and
MLL fusion protein–dependent AML.48,49 In keeping with this
proposed mechanism, established AML no longer requires the
presence of C/EBPa,50 suggesting that this transcription factor is
required to provide a permissive environment for the binding of
other factors.
Stratified medicine strategies51 are challenged by the genetic and
clinical heterogeneity in AML. This study has shown that in 2 types
of AML with fundamentally different gene regulatory networks,
C/EBPa can override the activities of the fusion proteins driving the
leukemic phenotype and reprogram the leukemic epigenome.
Identifying such critical nodes may provide a means by which the
complex genetic heterogeneity underlying the poor and disparate
outcomes of patients with AML can be tackled.
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